The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Unresectable Hepatocellular Carcinoma Global Market Report 2023, the unresectable hepatocellular carcinoma market is expected to show significant growth in the forecast period.

Key insights from the unresectable hepatocellular carcinoma market forecast include:

1. Market Size

The global unresectable hepatocellular carcinoma market is expected to grow from $1.29 billion in 2022 to $1.33 billion in 2023 at a compound annual growth rate (CAGR) of 2.7%. The unresectable hepatocellular carcinoma market is expected to reach $1.45 billion in 2027 at a CAGR of 2.2%.

2. Major Driver

The increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market going forward. Liver cancer refers to the healthy, functioning cells of the liver being taken over by tumor cells as they start to develop uncontrollably. For instance, In October 2022, according to the Journal of Hepatology, a Switzerland-based peer-reviewed scientific journal, globally, 830,200 people lost their lives to liver cancer by the year 2020. and there will probably be 1.4 million new cases of liver cancer diagnosed between 2020 and 2040, an increase of 55.0% in the number of new cases per year. Further, 1.3 million people will succumb to liver cancer in 2040, 56.4% more than in 2020. Therefore, the increasing prevalence of liver cancer is driving the growth of the unresectable hepatocellular carcinoma market.

View More On The Unresectable Hepatocellular Carcinoma Market Report 2023 – https://www.thebusinessresearchcompany.com/report/unresectable-hepatocellular-carcinoma-global-market-report

3. Key Trend

Product innovations are a key trend gaining popularity in the unresectable hepatocellular carcinoma market. Major companies operating in the unresectable hepatocellular carcinoma market are adopting innovative products to sustain their position in the market. For instance, in October 2022, AstraZeneca, a UK-based pharmaceutical and biotechnology company, launched FDA-approved Imjudo (tremelimumab) in combination with Imfinzi in the US for patients with unresectable liver cancer. The new treatment, known as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), consists of a single dosage of the anti-CTLA-4 antibody Imjudo 300mg combined with the anti-PD-L1 antibody Imfinzi 1500 mg every four weeks. Patients who received Imjudo and Imfinzi together had a 22% lower chance of passing away than those who received sorafenib.

4. Largest Region

North America was the largest region in the unresectable hepatocellular carcinoma market in 2022.

5. Major Players

Major players in the unresectable hepatocellular carcinoma market are Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, and Mendus AB.

Request A Sample Of The Global Unresectable Hepatocellular Carcinoma Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12079&type=smp 

Key Unresectable Hepatocellular Carcinoma Market Segments

The global unresectable hepatocellular carcinoma market is segmented –
1) By Type: Primary, Secondary, Benign Liver Growth
2) By Treatment Type: Chemotherapy, Molecularly Targeted Therapy, Immunotherapy, Other Treatments
3) By End-Users: Hospitals, Specialty Clinics, Cancer Centers

The Unresectable Hepatocellular Carcinoma Global Market Report 2023  provides an in-depth analysis on the unresectable hepatocellular carcinoma market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the unresectable hepatocellular carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Pain Management Devices And Therapies Global Market Report 2023
Metabolomics Global Market Report 2023
Monoclonal Antibodies MAbS Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model